TELOMIR PHARMACEUTICALS INC (TELO) Stock Income Statement
USA - NASDAQ:TELO - US87975F1049 - Common Stock
1.385 USD
+0.01 (+1.09%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 16.17M | 11.64M | 3.94M | 854.10K | 138.10K | |||
| Research and Development | 1.28M | 2.24M | 1.57M | 833.20K | 126.50K | |||
| Selling, General, and Administrative Expenses | 14.89M | 9.41M | 2.37M | 20.90K | 11.60K | |||
| Operating Income | -16.17M | -11.64M | -3.94M | -854.10K | -138.10K | |||
| Interest Income/Expense | 30.60K | -4.29M | -1.64M | N/A | N/A | |||
| Non Recurring Items | N/A | -600.00K | -7.49M | N/A | N/A | |||
| Income Before Taxes | -16.14M | -16.53M | -13.07M | -854.10K | -138.10K | |||
| Net Income | -16.14M | -16.53M | -13.07M | -854.10K | -138.10K | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.54 | -0.56 | -0.48 | -0.03 | 0.00 | |||
| Statistics | ||||||||
All data in USD